Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Remepy

Remepy

Series AUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$36.0Msum of rounds with a disclosed amount only
Named investors
8
Financing history
1 rounds
  1. Aug 12, 2026
    Series A · $36.0M (disclosed)
    Vine Ventures (participant)Qumra Capital (participant)Fresh Fund (participant)Tadmor Group (participant)Key1 Capital (participant)NFX (participant)Techaviv Management Co. (participant)Psymed Ventures Management LLC (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease”
Investors on record
8 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Aug 12, 2026
    Remepy announced Series A of $36,000,000, led by O.G
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company